Back to top
more

Medpace (MEDP)

(Real Time Quote from BATS)

$427.20 USD

427.20
29,864

+5.89 (1.40%)

Updated Jul 22, 2024 10:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Illumina (ILMN) Rises on Conclusion of GRAIL Divestment

by Zacks Equity Research

With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.

Medtronic (MDT) Shares Positive Data for MiniMed 780G System

by Zacks Equity Research

Medtronic (MDT) presents more compelling data showcasing the benefits of the MiniMed 780G system.

Abbott's (ABT) EPD Expansion Continues Despite FX Headwind

by Zacks Equity Research

Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.

Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval

by Zacks Equity Research

Valneva's (VALN) IXCHIQ, the world's only licensed chikungunya vaccine, is a critical tool in combating this public health threat.

Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes

by Zacks Equity Research

Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.

IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds

by Zacks Equity Research

IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.

Quest Diagnostics (DGX) Gains From New M&As Amid Competition

by Zacks Equity Research

In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.

Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System

by Zacks Equity Research

Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.

Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?

by Zacks Equity Research

Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.

Thermo Fisher's (TMO) New Buyouts Aid Growth, FX Issues Stay

by Zacks Equity Research

Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.

Boston Scientific (BSX) to Buy Silk Road, Boost Cardiology

by Zacks Equity Research

This acquisition is expected to enhance Boston Scientific's (BSX) market position and revenue streams in North America and Europe.

QIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions

by Zacks Equity Research

QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.

Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis

by Zacks Equity Research

Quest Diagnostics (DGX) completes the acquisition of PathAI Diagnostics, accelerating the adoption of AI and digital pathology to improve cancer diagnosis.

Charles River (CRL) Advances in T-Cell Therapy With New Alliance

by Zacks Equity Research

Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.

Medpace (MEDP) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

Medpace (MEDP) closed the most recent trading day at $395.95, moving +0.52% from the previous trading session.

QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays

by Zacks Equity Research

QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.

STERIS (STE) Gains From New Offerings, Macro Issues Ail

by Zacks Equity Research

STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.

BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial

by Zacks Equity Research

BrainsWay (BWAY) emphasizes the potential of the accelerated protocol, citing previous data suggesting comparable outcomes with traditional, longer protocols.

Zimmer Biomet (ZBH) Advances in GenAI Technology With RevelAi

by Zacks Equity Research

Zimmer Biomet (ZBH) and RevelAi Health have joined forces to solve social and clinician problems by commercializing RevelAi's patient care-management platform and care team dashboard for providers.

Thermo Fisher's (TMO) New Launch Supports Full Lab Automation

by Zacks Equity Research

Thermo Fisher's (TMO) first-of-its-kind innovation for CO2 incubators supports emerging automated cell therapy production processes.

Zimmer Biomet (ZBH) to Broaden Knee Surgery Line With New Alliance

by Zacks Equity Research

Zimmer Biomet (ZBH) joins forces with Think Surgical for the distribution of customized TMINI - Miniature Robotic System in the U.S. market.

Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation

by Zacks Equity Research

Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.

Neogen's (NEOG) MDS Secures New Contract From USDA FSIS

by Zacks Equity Research

Neogen's (NEOG) MDS gets recognized by the USDA FSIS as the primary method for the detection of Salmonella and Listeria monocytogenes testing for meat, poultry and egg products.

Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?

by Zacks Equity Research

The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.

Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch

by Zacks Equity Research

One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.